Bacterial Infections, Fungal Infections
Conditions
Keywords
Malditof, Malditof MS, matrix-assisted laser desorption ionization-time, identifying pathogens, randomized diagnostic trial
Brief summary
MALDI-TOF MS is capable of directly identifying bacteria and fungi in positive blood cultures, which may be beneficial to patient management. Therefore, MALDI-TOF MS is an important new technology that is becoming routine in developed countries. It is currently unknown whether MALDITOF MS improves diagnostics, costs and patient outcomes in developing countries. This study will assess the clinical impact of a MALDITOF MS system (Maldi Biotyper, Bruker, Germany) in the resource constrained setting of Vietnam and at what cost.
Detailed description
When an eligible specimen from a patient shows pathogen growth, the pathogen identification will be randomized to either MaldiTof or routine diagnostics ('diagnostic pipelines'). Randomization to MaldiTof or routine diagnostics will be 1:1 with stratification by hospital and specimen type (blood vs. other). Isolates grown from all eligible specimens of the same patient will be assigned to the same diagnostic pipeline as the first randomized specimen of that patient. Allocation to diagnostic arm will be assigned by a web based randomization program. When a pathogen is isolated from a positive eligible specimen, the laboratory technician will log onto the secure randomization program and enter the patient and specimen code. The random diagnostic pipeline allocation will then be generated, informed to the laboratory technician and logged in the study database. In the case of multiple specimens with pathogen growth for a single patient, the unique patient code will trigger the randomization program to generate the same diagnostic arm allocation as the previous sample(s).
Interventions
DEVICEMalditof
Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
OTHERRoutine clinical microbiology
Pathogens will be identified by the routine clinical microbiology of the hospital.
Sponsors
National Hospital for Tropical Diseases, Hanoi, Vietnam
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Oxford University Clinical Research Unit, Vietnam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Pathogen isolates from the following specimens: blood or diagnostic aspirates from normally sterile sites (including cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies).
Exclusion criteria
* Specimens negative for all pathogens * Specimens from sputum, respiratory or non-surgical wound swabs, nails, mucosal or skin biopsies, urine, fluid from drains, skin swabs and any others not listed in the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients on optimal antibiotic treatment | Within 24 hours of positive culture (first growth of an eligible specimen). | Optimal antibiotic treatment is defined as an antibiotic treatment for at least 48 hours since positive culture, targeted to the identified pathogen and later found to cover the organisms antimicrobial resistance profile, while avoiding unnecessary broad spectrum antibiotics (e.g. avoid carbapenems or multiple agents where other agents or single agents would provide sufficient coverage). This study aims to determine The proportion of patients on optimal antibiotic treatment within 24 hours of positive culture (first growth of an eligible specimen). |
Secondary
| Measure | Time frame |
|---|---|
| The total number of antibiotic switches | During treatment course, estimated to be 7-10 days. |
| The total duration of antibiotic treatment | During treatment course, estimated to be 7-10 days. |
| Length of ICU stay | During ICU admission, estimated to be 7 days |
| Length of hospital stay | During hospital admission, estimated to be 12 days |
| Patient outcome: death, palliative discharge, survived with sequelae, recovered | On or before discharge, estimated to be at 12 days |
| Costs of microbiological testing | On or before discharge, estimated to be at 12 days |
| Treatment and hospital costs | On or before discharge, estimated to be at 12 days |
Other
| Measure | Time frame |
|---|---|
| The time from first recognition of isolate growth to issue of pathogen identification report | Estimated 0-12 hours |
| The time from specimen collection to issue of pathogen identification report | Estimated 24-48 hours |
| Time from first specimen collection to discharge | Estimated to be 12 days |
| Time from first pathogen identification to discharge | Estimated to be 10 days |
| Time from specimen collection of positive eligible specimen to optimal antibiotic treatment | During hospital admission, estimated to be 0-48 hours |
| Time from first growth of an eligible specimen to optimal antibiotic treatment. | During hospital admission, estimated to be 0-48 hours |
Countries
Vietnam
Outcome results
None listed